Skip to main content
main-content

Sodium-glucose co-transporter-2 inhibitors

News

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

06-12-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

06-09-2019 | SGLT2 inhibitors | ADA 2019 | News

SGLT2 inhibitor, GLP-1 receptor agonist risk–benefits explored in older adults

Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.

Read more

Related topics

Superior

Related

Specific

Opinion

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

09-12-2018 | Diet | Commentary | Article

Diet–drug interactions: Why two rights can make a wrong

Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.

01-16-2018 | Type 1 diabetes | Editorial | Article

Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

In depth

11-16-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Original research

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

Case reports

05-28-2018 | Lifestyle interventions | Case report | Article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

03-29-2018 | Pregnancy | Case report | Article

Empagliflozin, metformin, and insulin degludec, during pregnancy: A case report

Formoso G et al. Acta Diabetol 2018; 55: 759. doi: 10.1007/s00592-018-1134-y

01-15-2018 | Prader-Willi syndrome | Case report | Article

Effectiveness of sodium-glucose cotransporter-2 inhibitor as an add-on drug to GLP-1 receptor agonists for glycemic control of a patient with Prader–Willi syndrome: A case report

Horikawa Y et al. Diabetes Ther 2018; 9: 421. doi: 10.1007/s13300-018-0369-5

Image Credits